AVTX

Avalo Therapeutics, Inc.

Name: Avalo Therapeutics, Inc. insider trading (SEC Form 4) history
Creator: U.S. Securities and Exchange Commission

SEC CIK 1534120

$13.67 −14.3% · 90 days

90-day buys

0 open-market

90-day sells

$5.86M

28 open-market

Net insider flow

−$5.86M

Net selling

Filings shown

Most recent

At a glance

Over the last 90 days, insiders at AVTX have sold a net $5.86M of stock (0 open-market buys vs 28 sells).

Largest recent trade: Doyle Mittie sold $952.7K of AVTX, trimming their stake 58%.

Most active filer: Doyle Mittie, with 19 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for AVTX, newest first

View on SEC EDGAR ↗

AVTX

Avalo Therapeutics, Inc.

Option exercise Doyle Mittie · Chief Medical Officer · Option exercise · filed 1w ago ΔOwn +1.4%

+$5.5K

679 sh @ $8

AVTX

Avalo Therapeutics, Inc.

Sell Doyle Mittie · Chief Medical Officer · Open-market sale · filed 1w ago ΔOwn −1.4%

Doyle Mittie sold $10.9K of AVTX, trimming their stake 1%.

−$10.9K

679 sh @ $16

AVTX

Avalo Therapeutics, Inc.

Grant/award Riley Jennifer · Chief Strategy Officer · Grant/award · filed 2w ago ΔOwn +999%

+$0

34,200 sh

AVTX

Avalo Therapeutics, Inc.

Grant/award Sullivan Christopher Ryan · Chief Financial Officer · Grant/award · filed 2w ago ΔOwn +999%

+$0

39,900 sh

AVTX

Avalo Therapeutics, Inc.

Grant/award VARKI PAUL · Chief Legal Officer · Grant/award · filed 2w ago ΔOwn +669%

+$0

24,300 sh

AVTX

Avalo Therapeutics, Inc.

Grant/award Doyle Mittie · Chief Medical Officer · Grant/award · filed 2w ago ΔOwn +999%

+$0

43,500 sh

AVTX

Avalo Therapeutics, Inc.

Grant/award NEIL GARRY ARTHUR · Director, Chief Executive Officer · Grant/award · filed 2w ago ΔOwn +111%

+$0

100,200 sh

AVTX

Avalo Therapeutics, Inc.

Option exercise Doyle Mittie · Chief Medical Officer · Option exercise · filed 3w ago ΔOwn +83%

+$38K

3,000 sh @ $13

AVTX

Avalo Therapeutics, Inc.

Sell Doyle Mittie · Chief Medical Officer · Open-market sale · filed 3w ago ΔOwn −45%

Doyle Mittie sold $56.3K of AVTX, trimming their stake 45%.

−$56.3K

3,000 sh @ $19

AVTX

Avalo Therapeutics, Inc.

Option exercise Sullivan Christopher Ryan · Chief Financial Officer · Option exercise · filed May 11, 2026 ΔOwn +999%

+$183.8K

18,606 sh @ $10

AVTX

Avalo Therapeutics, Inc.

Sell Sullivan Christopher Ryan · Chief Financial Officer · Open-market sale · filed May 11, 2026 ΔOwn −98%

Sullivan Christopher Ryan sold $448.8K of AVTX, trimming their stake 98%.

−$448.8K

18,606 sh @ $24

AVTX

Avalo Therapeutics, Inc.

Option exercise VARKI PAUL · Chief Legal Officer · Option exercise · filed May 7, 2026 ΔOwn +999%

+$839.4K

62,500 sh @ $13

AVTX

Avalo Therapeutics, Inc.

Option exercise VARKI PAUL · Chief Legal Officer · Option exercise · filed May 7, 2026 ΔOwn +19%

+$101K

12,563 sh @ $8

AVTX

Avalo Therapeutics, Inc.

Sell VARKI PAUL · Chief Legal Officer · Open-market sale · filed May 7, 2026 ΔOwn −47%

Varki Paul sold $706.8K of AVTX, trimming their stake 47%.

−$706.8K

37,375 sh @ $19

AVTX

Avalo Therapeutics, Inc.

Sell VARKI PAUL · Chief Legal Officer · Open-market sale · filed May 7, 2026 ΔOwn −13%

Varki Paul sold $102.8K of AVTX, trimming their stake 13%.

−$102.8K

5,196 sh @ $20

AVTX

Avalo Therapeutics, Inc.

Sell VARKI PAUL · Chief Legal Officer · Open-market sale · filed May 7, 2026 ΔOwn −63%

Varki Paul sold $484.5K of AVTX, trimming their stake 63%.

−$484.5K

22,839 sh @ $21

AVTX

Avalo Therapeutics, Inc.

Sell VARKI PAUL · Chief Legal Officer · Open-market sale · filed May 7, 2026 ΔOwn −70%

Varki Paul sold $210K of AVTX, trimming their stake 70%.

−$210K

9,253 sh @ $23

AVTX

Avalo Therapeutics, Inc.

Sell VARKI PAUL · Chief Legal Officer · Open-market sale · filed May 7, 2026 ΔOwn −9.9%

Varki Paul sold $9.5K of AVTX, trimming their stake 10%.

−$9.5K

400 sh @ $24

AVTX

Avalo Therapeutics, Inc.

Option exercise Sullivan Christopher Ryan · Chief Financial Officer · Option exercise · filed May 7, 2026 ΔOwn +999%

+$377.9K

47,000 sh @ $8

AVTX

Avalo Therapeutics, Inc.

Sell Sullivan Christopher Ryan · Chief Financial Officer · Open-market sale · filed May 7, 2026 ΔOwn −29%

Sullivan Christopher Ryan sold $256.7K of AVTX, trimming their stake 29%.

−$256.7K

13,834 sh @ $19

AVTX

Avalo Therapeutics, Inc.

Sell Sullivan Christopher Ryan · Chief Financial Officer · Open-market sale · filed May 7, 2026 ΔOwn −37%

Sullivan Christopher Ryan sold $238.1K of AVTX, trimming their stake 37%.

−$238.1K

12,347 sh @ $19

AVTX

Avalo Therapeutics, Inc.

Sell Sullivan Christopher Ryan · Chief Financial Officer · Open-market sale · filed May 7, 2026 ΔOwn −13%

Sullivan Christopher Ryan sold $56.1K of AVTX, trimming their stake 13%.

−$56.1K

2,700 sh @ $21

AVTX

Avalo Therapeutics, Inc.

Sell Sullivan Christopher Ryan · Chief Financial Officer · Open-market sale · filed May 7, 2026 ΔOwn −50%

Sullivan Christopher Ryan sold $197K of AVTX, trimming their stake 50%.

−$197K

9,219 sh @ $21

AVTX

Avalo Therapeutics, Inc.

Sell Sullivan Christopher Ryan · Chief Financial Officer · Open-market sale · filed May 7, 2026 ΔOwn −95%

Sullivan Christopher Ryan sold $200.9K of AVTX, trimming their stake 95%.

−$200.9K

8,900 sh @ $23

AVTX

Avalo Therapeutics, Inc.

Option exercise Doyle Mittie · Chief Medical Officer · Option exercise · filed May 7, 2026 ΔOwn +999%

+$985.5K

77,905 sh @ $13

AVTX

Avalo Therapeutics, Inc.

Option exercise Doyle Mittie · Chief Medical Officer · Option exercise · filed May 7, 2026 ΔOwn +35%

+$230.3K

28,650 sh @ $8

AVTX

Avalo Therapeutics, Inc.

Sell Doyle Mittie · Chief Medical Officer · Open-market sale · filed May 7, 2026 ΔOwn −25%

Doyle Mittie sold $496.4K of AVTX, trimming their stake 25%.

−$496.4K

27,538 sh @ $18

AVTX

Avalo Therapeutics, Inc.

Sell Doyle Mittie · Chief Medical Officer · Open-market sale · filed May 7, 2026 ΔOwn −6.1%

Doyle Mittie sold $98.3K of AVTX, trimming their stake 6%.

−$98.3K

5,000 sh @ $20

AVTX

Avalo Therapeutics, Inc.

Sell Doyle Mittie · Chief Medical Officer · Open-market sale · filed May 7, 2026 ΔOwn −58%

Doyle Mittie sold $952.7K of AVTX, trimming their stake 58%.

−$952.7K

44,944 sh @ $21

AVTX

Avalo Therapeutics, Inc.

Sell Doyle Mittie · Chief Medical Officer · Open-market sale · filed May 7, 2026 ΔOwn −58%

Doyle Mittie sold $426.1K of AVTX, trimming their stake 58%.

−$426.1K

19,015 sh @ $22

About AVTX insider activity

This page tracks every recent Form 4 filed for Avalo Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is AVTX insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Avalo Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.